Navigation Links
Gene vaccine for Alzheimer's disease shows promising results

UT Southwestern Medical Center at Dallas researchers have found a way of stimulating the immune systems of mice to fight against amyloid proteins that cause the devastating plaques that are characteristic of Alzheimer's disease. For years scientists have examined the possibility of using a protein-based vaccine to slow the progression of the disease in its early stages. UT Southwestern researchers have created a gene-based vaccine aimed at stimulating the immune systems of mice to potentially fight off plaque-causing amyloid protein in the brain. Their findings appear in today's issue of the Archives of Neurology.

"Previous Alzheimer's vaccines were protein-based," said Dr. Baoxi Qu, the study's lead author and assistant professor in the Center for Biomedical Inventions and internal medicine. "We wanted to try a DNA-based genetic vaccine instead to see if we could enhance the immune response." Although prior studies of amyloid protein vaccination had shown some slowing in the plaque buildup, negative side effects also occurred in a handful of patients. Some had autoimmune responses that caused encephalitis. The key in the UT Southwestern study was finding another way to vaccinate patients without stimulating the body's own immune cytotoxic T cells, said Dr. Roger Rosenberg, a study author and director of the Alzheimer's Disease Center. "This dilemma was discussed with my colleagues, and we decided to try vaccination with an amyloid gene, rather than the amyloid protein vaccine," said Dr. Rosenberg. The UT Southwestern researchers vaccinated mice with a "gene gun." The gene gun and gene-vaccination technologies were invented by Dr. Stephen Albert Johnston, director of the Center for Biomedical Inventions and senior author of the latest study. "We have been developing ways to use gene-immunization to manipulate the immune response," Dr. Johnston said. "This study was the first step to see if we can apply these techni ques to create a safe and effective Alzheimer's vaccine." Said Dr. Rosenberg: "When we vaccinated the mice with the mouse form of the amyloid gene, they made lots of antibodies without stimulating cytotoxic T cells. When we get to human studies, we hope to show that humans can make human antibodies against the amyloid as well." Current treatments for Alzheimer's disease focus on the symptoms since no therapies have been clinically proven to slow or prevent progression of the disease. Amyloid protein deposits are present in the early phase of the disease - a fact that suggests a gene vaccination would be a step forward in slowing the progression of dementia. From the mouse studies and in previous clinical trials of patients with Alzheimer's disease, immunization with amyloids slowed the buildup of plaque in the brain and appeared to slow cognitive loss. "Although human clinical trials are still at least two years out, theoretically, we are on the right track," he said.
'"/>

Source:UT Southwestern Medical Center at Dallas


Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Influenza vaccine uses insect cells to speed development
5. Norovirus, AIDS vaccine and Hepatitis Virus
6. HIV vaccine trial breaks ground for future research
7. Live vaccines more effective against horse herpes virus
8. NIAID begins clinical trial of West Nile virus vaccine
9. Designing vaccines by computer
10. Wake Forest scientists find new combination vaccine effective against plague
11. New vaccine means bye-bye to bacteria in the lung

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... PARSIPPANY, N.J. , Jan. 20, 2017 /PRNewswire/ ... the "Company"), a company that provides clinically useful ... that it has entered into a securities purchase ... aggregate of 855,000 shares of common stock in ... placement, the Company has agreed to sell to ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port ... The Wistar Institute, and Sanguis, launched by a trio of students from the University ... is developing a treatment for a chronic viral infection and its associated diseases, with ...
(Date:1/20/2017)... ... January 20, 2017 , ... SpineFrontier, ... next evolution in spinal fusion, the MISquito Percutaneous Pedicle Screw System (part ... SpineFrontier is focused on technique driven product solutions that provide maximum efficiency ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
Breaking Biology Technology: